LATEST NEWS IN PROSTATE CANCER

PCRI PCRI

What Hollywood Is Not Telling You About Prostate Cancer

Prostate cancer management and treatment is a rapidly evolving field as technology and medical knowledge expands. Treatment of this disease has changed drastically over the past ten years. Knowledge has brought about a deeper understanding of the nature of the disease and allows many patients to safely avoid the invasive treatments that were the only option in times past.

Read More
PCRI PCRI

FDA Approves Olaparib for HRR Gene-Mutated Metastatic Castration-Resistant Prostate Cancer

On May 19, 2020, the Food and Drug Administration approved olaparib (LYNPARZA, AstraZeneca Pharmaceuticals, LP) for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC), who have progressed following prior treatment with enzalutamide or abiraterone.

Read More
PCRI PCRI

FDA Grants Accelerated Approval to Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

On May 15, 2020, the Food and Drug Administration granted accelerated approval to rucaparib (RUBRACA, Clovis Oncology, Inc.) for patients with deleterious BRCA mutation (germline and/or somatic)-associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy.

Read More
PCRI PCRI

How to Handle Rare Radiation Complications

Radiation for prostate cancer treatment can be either external or internal. External beam radiation is delivered from a machine outside of the body. Internal radiation treatments are commonly called brachytherapy, seed implants, or interstitial radiation therapy….

Read More